Taken together, these metabolic changes induced by inhibiting deacylation in control hearts recapitulate the metabolic phenotype of the T2D heart, indicating a critical role for CD36 S-acylation in the development of cardiac metabolic dysfunction in diabetes. Here, CD36 is linked to diabetes mellitus.